SCOPE Plus: iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma (clinicaltrials.gov) - Sep 12, 2026 - P3 | N=550 | Not yet recruiting | Sponsor: Scancell Ltd
New P3 trial • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor • BRAF
|